Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.70 |
| ▸ | IKZF3 | Q9UKT9 | 9/20 | 0.69 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.69 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.69 |
| ▸ | BRD4 | O60885 | 1/20 | 0.69 |
| ▸ | TNF | P01375 | 1/20 | 0.69 |
| ▸ | IL1B | P01584 | 1/20 | 0.69 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.52 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21107124 | 1.00 | CRBN (0.70) | CRBNIKZF3IKZF1DDB1BRD4 | |
| SCHEMBL21107638 | 1.00 | CRBN (0.70) | CRBNIKZF3IKZF1DDB1BRD4 | |
| SCHEMBL19612026 | 0.93 | CRBN (0.61) | CRBNIKZF3IKZF1DDB1BRD4 | |
| SCHEMBL19612025 | 0.93 | CRBN (0.61) | CRBNIKZF3IKZF1DDB1BRD4 | |
| SCHEMBL23594393 | 0.91 | CRBN (0.67) | CRBNIKZF3IKZF1DDB1BRD4 | |
| SCHEMBL24764835 | 0.91 | CRBN (0.67) | CRBNIKZF3IKZF1DDB1BRD4 | |
| Hydrochloric Acid SCHEMBL27777888 | 0.90 | CRBN (0.68) | CRBNIKZF3IKZF1DDB1BRD4 | |
| SCHEMBL24765458 | 0.89 | CRBN (0.65) | CRBNIKZF3IKZF1DDB1BRD4 | |
| SCHEMBL25726981 | 0.89 | CRBN (0.65) | CRBNIKZF3IKZF1DDB1BRD4 | |
| SCHEMBL25653782 | 0.89 | CRBN (0.65) | CRBNIKZF3IKZF1DDB1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240217988-A1 | ESTROGEN RECEPTOR ANTAGONIST | SHENZHEN FORWARD PHARMACEUTICALS CO., LIMITED (CN) | 2024-07-04 | — | — | US | disclosed |
| WO-2024081311-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024064358-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024035780-A1 | AKR1C3 TARGETED HETEROBIFUNCTIONAL SMALL MOLECULE PROTEOLYSIS TARGETING CHIMERAS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2023129564-A9 | DEGRADERS OF GRK2 AND USES THEREOF | CYGNAL THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024026083-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023249968-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-DJPYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20200109149-A1 | SMALL MOLECULE MDM2 PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-04-09 | — | — | US | disclosed |
| US-20200048276-A9 | MYC MODULATORS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-02-13 | — | — | US | disclosed |
| US-20190263827-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190135801-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BIOVENTURES, LLC | 2019-05-09 | — | — | US | disclosed |
| US-20190127387-A1 | MDM2 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190054097-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | BIOVENTURES, LLC | 2019-02-21 | — | — | US | disclosed |
| WO-2017184995-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BIOVENTURES, LLC (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | MDM2, CD74, TNFSF10 | CRBN 151/4885IKZF3 231/4885IKZF1 345/4885 |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | CRBN 1994/4885IKZF3 3479/4885IKZF1 2280/4885 |
| US-20200048276-A9 | MYC MODULATORS AND USES THEREOF | MYC, MYCBP, MYCBP2 | CRBN 263/4885IKZF3 491/4885IKZF1 341/4885 |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | CRBN 3449/4885IKZF3 4014/4885IKZF1 3513/4885 |
| US-20190263827-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | BRD4, BRD1, BET1 | CRBN 114/4885IKZF3 206/4885IKZF1 291/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | CRBN 154/4885IKZF3 653/4885IKZF1 508/4885 |
| US-20240217988-A1 | ESTROGEN RECEPTOR ANTAGONIST | GPER1, ESR1, ESR2 | CRBN 2823/4885IKZF3 2003/4885IKZF1 967/4885 |
| US-20190135801-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BCL2, BAX, BCL2L1 | CRBN 520/4885IKZF3 1083/4885IKZF1 731/4885 |
| US-20200109149-A1 | SMALL MOLECULE MDM2 PROTEIN DEGRADERS | MDM2, TP53, RBX1 | CRBN 40/4885IKZF3 1162/4885IKZF1 1151/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885IKZF3 135/4885IKZF1 41/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885IKZF3 135/4885IKZF1 41/4885 |
| US-20190054097-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | TP53, MCL1, LIMS1 | CRBN 1187/4885IKZF3 2102/4885IKZF1 1798/4885 |
| US-20190127387-A1 | MDM2 PROTEIN DEGRADERS | MDM2, TP53, TP53BP1 | CRBN 605/4885IKZF3 555/4885IKZF1 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.